Prostate-specific membrane antigen is produced in tumor-associated neovasculature
- PMID: 10537328
Prostate-specific membrane antigen is produced in tumor-associated neovasculature
Abstract
Prostate-specific membrane antigen (PSMA), a type II transmembrane protein, was originally thought to be strictly expressed in prostatic tissue, but recent studies have demonstrated PSMA protein expression in nonprostatic tumor neovasculature as well. Using immunohistochemistry, reverse transcription-PCR assays, and in situ hybridization, we have demonstrated PSMA mRNA transcripts and protein expression in the endothelium of tumor-associated neovasculature of multiple nonprostatic solid malignancies. In addition, we found no PSMA mRNA or protein expression in the vascular endothelial cells of corresponding benign tissue examples. Our findings expand the possible therapeutic role of PSMA and establish it as a unique biomarker specifically produced and expressed by tumor-associated neovasculature but not produced or expressed by normal vessels.
Similar articles
-
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.Cancer Res. 1999 Jul 1;59(13):3192-8. Cancer Res. 1999. PMID: 10397265
-
Prostate-specific membrane antigen expression in normal and malignant human tissues.Clin Cancer Res. 1997 Jan;3(1):81-5. Clin Cancer Res. 1997. PMID: 9815541
-
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.Int J Cancer. 2003 Nov 1;107(2):323-9. doi: 10.1002/ijc.11402. Int J Cancer. 2003. PMID: 12949815
-
[Detection of PSA mRNA and PSMA mRNA by RT-PCR].Nihon Rinsho. 2002 Dec;60 Suppl 11:151-5. Nihon Rinsho. 2002. PMID: 12599562 Review. Japanese. No abstract available.
-
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.Urology. 1998 Oct;52(4):637-40. doi: 10.1016/s0090-4295(98)00278-7. Urology. 1998. PMID: 9763084 Review.
Cited by
-
Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for _targeting PSMA.Bioconjug Chem. 2016 Jun 15;27(6):1447-55. doi: 10.1021/acs.bioconjchem.5b00679. Epub 2016 May 9. Bioconjug Chem. 2016. PMID: 27076393 Free PMC article.
-
Multimodality Imaging of Prostate Cancer.J Nucl Med. 2019 Oct;60(10):1350-1358. doi: 10.2967/jnumed.119.228320. Epub 2019 Sep 3. J Nucl Med. 2019. PMID: 31481573 Free PMC article. Review.
-
_targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.Breast Cancer Res. 2019 Oct 22;21(1):116. doi: 10.1186/s13058-019-1205-1. Breast Cancer Res. 2019. PMID: 31640747 Free PMC article.
-
Clinical Cancer Nanomedicine.Nano Today. 2019 Apr;25:85-98. doi: 10.1016/j.nantod.2019.02.005. Epub 2019 Mar 6. Nano Today. 2019. PMID: 31360214 Free PMC article.
-
Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition.Jpn J Cancer Res. 2002 Oct;93(10):1154-63. doi: 10.1111/j.1349-7006.2002.tb01218.x. Jpn J Cancer Res. 2002. PMID: 12417046 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous